{"id":63207,"date":"2026-04-15T20:38:17","date_gmt":"2026-04-15T12:38:17","guid":{"rendered":"https:\/\/flcube.com\/?p=63207"},"modified":"2026-04-15T20:38:18","modified_gmt":"2026-04-15T12:38:18","slug":"xuanzhu-biopharma-receives-nmpa-approval-for-phase-iii-trial-of-anaprazole-based-quadruple-therapy-against-h-pylori","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63207","title":{"rendered":"Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori"},"content":{"rendered":"\n<p><strong>Xuanzhu Biopharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2575:HKG\">HKG: 2575<\/a>) announced it has received regulatory clearance from the <strong>National Medical Products Administration (NMPA)<\/strong> to initiate a <strong>Phase III clinical study<\/strong> evaluating its <strong>B-quadruple therapy<\/strong> containing <strong>anaprazole<\/strong> for the <strong>eradication of Helicobacter pylori (H. pylori)<\/strong> infection.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575)<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Phase III clinical trial authorization<\/td><\/tr><tr><td><strong>Study Phase<\/strong><\/td><td>Phase III<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>B-quadruple therapy containing anaprazole<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Eradication of Helicobacter pylori (H. pylori) infection<\/td><\/tr><tr><td><strong>Previous Approval<\/strong><\/td><td>June 2023 for duodenal ulcer treatment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<p><strong>Anaprazole<\/strong> is a <strong>proton pump inhibitor (PPI)<\/strong> belonging to the <strong>benzimidazole class<\/strong> of compounds with a well-defined mechanism:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Action<\/strong>: Inhibits gastric acid secretion through suppression of <strong>H\u207a-K\u207a-ATPase<\/strong> activity in gastric parietal cells<\/li>\n\n\n\n<li><strong>Molecular Effect<\/strong>: Reduces proton transport capacity, creating optimal conditions for H. pylori eradication<\/li>\n\n\n\n<li><strong>Therapeutic Class<\/strong>: Benzimidazole-based proton pump inhibitor<\/li>\n\n\n\n<li><strong>Previous Indication<\/strong>: Approved in China (June 2023) for <strong>duodenal ulcer<\/strong> treatment<\/li>\n<\/ul>\n\n\n\n<p>The Phase III trial will evaluate anaprazole as part of a <strong>quadruple therapy regimen<\/strong>, which typically combines a PPI with multiple antibiotics to achieve higher eradication rates against increasingly resistant H. pylori strains.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-strategic-rationale\">Market Opportunity &amp; Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High Disease Burden<\/strong>: H. pylori infects approximately 50% of the global population, with particularly high prevalence in Asia<\/li>\n\n\n\n<li><strong>Treatment Resistance<\/strong>: Rising antibiotic resistance has reduced efficacy of traditional triple therapy regimens, creating demand for more effective quadruple approaches<\/li>\n\n\n\n<li><strong>Commercial Expansion<\/strong>: Successful Phase III results would significantly expand anaprazole&#8217;s market potential beyond duodenal ulcers to the much larger H. pylori eradication market<\/li>\n\n\n\n<li><strong>Healthcare Impact<\/strong>: Effective H. pylori eradication reduces risks of peptic ulcers, gastric cancer, and other serious gastrointestinal complications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<p>The H. pylori treatment market is evolving toward more complex regimens due to increasing resistance patterns. Key competitive factors include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Eradication Rates<\/strong>: Superior efficacy compared to existing triple and quadruple therapies<\/li>\n\n\n\n<li><strong>Safety Profile<\/strong>: Favorable tolerability with minimal drug interactions<\/li>\n\n\n\n<li><strong>Dosing Convenience<\/strong>: Simplified regimens that improve patient compliance<\/li>\n\n\n\n<li><strong>Cost-Effectiveness<\/strong>: Value proposition relative to imported alternatives<\/li>\n<\/ul>\n\n\n\n<p>Xuanzhu&#8217;s strategy leverages its established PPI compound in a novel combination approach, potentially offering improved outcomes in the challenging H. pylori eradication setting.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-outlook\">Industry Outlook<\/h2>\n\n\n\n<p>China&#8217;s gastrointestinal therapeutics market represents significant growth potential, with H. pylori eradication being a major focus area due to the country&#8217;s high gastric cancer incidence. The shift toward quadruple therapy regimens reflects global trends in managing increasingly resistant H. pylori infections.<\/p>\n\n\n\n<p>If successful, Xuanzhu&#8217;s B-quadruple therapy could become a new standard of care in China&#8217;s H. pylori treatment landscape, while also supporting potential international expansion opportunities.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and market opportunities for anaprazole-based quadruple therapy. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and changing treatment guidelines in the H. pylori market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041500008_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026041500008_c.\"><\/object><a id=\"wp-block-file--media-43683d86-d519-413e-924b-07b9a3330745\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041500008_c.pdf\">2026041500008_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041500008_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-43683d86-d519-413e-924b-07b9a3330745\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced it has received regulatory clearance from the National&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,622,4408,670],"class_list":["post-63207","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-gastroenterology","tag-hkg-2575","tag-xuanzhu-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced it has received regulatory clearance from the National Medical Products Administration (NMPA) to initiate a Phase III clinical study evaluating its B-quadruple therapy containing anaprazole for the eradication of Helicobacter pylori (H. pylori) infection.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63207\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori\" \/>\n<meta property=\"og:description\" content=\"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced it has received regulatory clearance from the National Medical Products Administration (NMPA) to initiate a Phase III clinical study evaluating its B-quadruple therapy containing anaprazole for the eradication of Helicobacter pylori (H. pylori) infection.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63207\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-15T12:38:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T12:38:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63207#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63207\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori\",\"datePublished\":\"2026-04-15T12:38:17+00:00\",\"dateModified\":\"2026-04-15T12:38:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63207\"},\"wordCount\":490,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Gastroenterology\",\"HKG: 2575\",\"Xuanzhu Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63207#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63207\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63207\",\"name\":\"Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-15T12:38:17+00:00\",\"dateModified\":\"2026-04-15T12:38:18+00:00\",\"description\":\"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced it has received regulatory clearance from the National Medical Products Administration (NMPA) to initiate a Phase III clinical study evaluating its B-quadruple therapy containing anaprazole for the eradication of Helicobacter pylori (H. pylori) infection.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63207#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63207\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63207#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori - Insight, China&#039;s Pharmaceutical Industry","description":"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced it has received regulatory clearance from the National Medical Products Administration (NMPA) to initiate a Phase III clinical study evaluating its B-quadruple therapy containing anaprazole for the eradication of Helicobacter pylori (H. pylori) infection.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63207","og_locale":"en_US","og_type":"article","og_title":"Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori","og_description":"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced it has received regulatory clearance from the National Medical Products Administration (NMPA) to initiate a Phase III clinical study evaluating its B-quadruple therapy containing anaprazole for the eradication of Helicobacter pylori (H. pylori) infection.","og_url":"https:\/\/flcube.com\/?p=63207","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-15T12:38:17+00:00","article_modified_time":"2026-04-15T12:38:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63207#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63207"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori","datePublished":"2026-04-15T12:38:17+00:00","dateModified":"2026-04-15T12:38:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63207"},"wordCount":490,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Gastroenterology","HKG: 2575","Xuanzhu Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63207#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63207","url":"https:\/\/flcube.com\/?p=63207","name":"Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-15T12:38:17+00:00","dateModified":"2026-04-15T12:38:18+00:00","description":"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced it has received regulatory clearance from the National Medical Products Administration (NMPA) to initiate a Phase III clinical study evaluating its B-quadruple therapy containing anaprazole for the eradication of Helicobacter pylori (H. pylori) infection.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63207#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63207"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63207#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63207"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63207\/revisions"}],"predecessor-version":[{"id":63209,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63207\/revisions\/63209"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}